Skip to main content
Inify Laboratories AB logo

Inify Laboratories AB — Investor Relations & Filings

Ticker · INIFY ISIN · SE0017486103 LEI · 549300306YYJ3BX3VB98 ST Human health and social work activities
Open in API
Filings indexed 339 across all filing types
Latest filing 2024-10-23 Earnings Release
Country SE Sweden
Listing ST INIFY

About Inify Laboratories AB

https://www.inify.com/

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. The company utilizes a fully digital, standardized, and AI-supported workflow for histopathology analysis. This integrated service model is designed to optimize the entire diagnostic process, from sample receipt to final report, ensuring high quality and significantly reduced turnaround times for clinical partners. Initially focused on prostate cancer, the company has expanded its diagnostic capabilities to include other areas such as gastroenterology. By streamlining the clinical pathway, Inify Laboratories enables healthcare providers to receive faster results, which facilitates earlier patient follow-up and treatment planning.

Recent filings

Filing Released Lang Actions
Inify Laboratories: Etablering i Storbritannien och expansion inom mag-tarmdiagnostik
Earnings Release Classification · 95% confidence The document is a press release dated October 23, 2024, detailing strategic business updates (UK expansion, entry into gastrointestinal diagnostics) and providing a brief summary of the third-quarter financial results (revenue figures, cash position). The final paragraph explicitly states that the information constitutes 'insider information' under the EU Market Abuse Regulation (MAR) and is being made public via a 'börsmeddelande' (stock exchange announcement). This structure—strategic news combined with brief financial highlights and a MAR disclosure—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it provides key financial highlights (Q3 revenue, YTD revenue, cash balance) immediately following strategic news, it aligns best with the 'Earnings Release' (ER) definition, which covers the initial announcement of periodical financial results (key highlights only). It is not a full 'Interim Report' (IR) or 'Annual Report' (10-K). Given the context of a stock exchange announcement containing financial metrics, ER is the most appropriate fit, although RNS could also apply if ER was not available. Since ER is defined as the 'Initial announcement of quarterly/periodical financial results (key highlights only)', this fits well. Q3 2024
2024-10-23 Swedish
Inify Laboratories: Etablering i Storbritannia og utvidelse til mage/tarm diagnostikk
Capital/Financing Update Classification · 95% confidence The document is a press release dated October 23, 2024, announcing strategic business updates: expansion into the UK, entry into gastrointestinal diagnostics, and a planned SEK 150 million rights issue (fundraising). It also briefly mentions Q3 sales figures (SEK 2.8 million). The text concludes by stating the information is considered inside information under MAR and was published as a 'børsmelding' (stock exchange announcement). Since it is a short announcement detailing strategic moves and financing, and not the full quarterly report (IR) or annual report (10-K), it best fits the category for Capital/Financing Update (CAP) due to the explicit mention of the SEK 150 million rights issue, or potentially a general Regulatory Filing (RNS) if the financing aspect was secondary. Given the prominence of the financing plan (emisjon) alongside strategic expansion, CAP is a strong fit. However, because it is a general announcement covering multiple strategic points (expansion, financing, brief results) and is explicitly labeled as an information disclosure under MAR, it functions as a broad regulatory announcement. Since 'CAP' specifically covers fundraising/financing activities, and this document heavily features a planned 'emisjon' (rights issue), I will classify it as CAP, as this is a primary driver of the announcement. If it were purely strategic without the financing, RNS might be considered, but the financing component points strongly to CAP.
2024-10-23 Norwegian
Inify Laboratories: Establishment in the United Kingdom and expansion into gastrointestinal diagnostics
Regulatory Filings Classification · 95% confidence The document is a press release dated October 23, 2024, announcing strategic business updates: establishment in the UK, expansion into gastrointestinal diagnostics, and a brief summary of Q3 sales figures (SEK 2.8 million). It also mentions initiating a funding process via a share issue of SEK 150 million. The text concludes by stating, 'This stock exchange announcement was published by Ann-Charlotte Linderoth, Inify Laboratories AB on the time and date provided.' This structure strongly indicates a general regulatory announcement or press release regarding corporate activities, financing, and performance highlights, rather than a full statutory report (like 10-K or IR) or a dedicated earnings release (ER) which usually focuses solely on the numbers. Since it covers multiple strategic and financial updates and is explicitly labeled as a 'stock exchange announcement,' the most appropriate general category is Regulatory Filings (RNS), as it doesn't fit the more specific categories like CAP (which focuses only on financing) or ER (which focuses only on results). Given the length (under 5,000 chars) and the nature of the content (announcing news), RNS is the best fit among the available options for a general corporate disclosure.
2024-10-23 English
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport andra kvartalet 2024' (Interim Report for the second quarter of 2024) for Inify Laboratories. It contains comprehensive financial statements, key performance indicators (KPIs), management commentary, and operational updates for the specified period. It is a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report. Q2 2024
2024-08-21 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the second quarter 2024' and contains detailed financial statements, key figures, management commentary, and operational updates for the specified period. It is a comprehensive report rather than a short announcement, thus fitting the definition of an Interim/Quarterly Report. Q2 2024
2024-08-21 English
INIFY Laboratories: Inntektsvekst på 62 prosent og sterk internasjonal interesse
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim report for the second quarter 2024' and contains detailed financial statements, key figures, management commentary, and operational updates for the specified period. It is a comprehensive report rather than a short announcement, thus fitting the definition of an Interim/Quarterly Report. Q2 2024
2024-08-21 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.